However, the clinical outcome of AML patients who received the Bcl-2 inhibitor ABT-199 (also known as venetoclax), which has been approved by the FDA for the treatment of chronic lymphocytic leukemia, as monotherapy was discouraging4. The gene discussed is BCL2; the disease is acute myeloid leukemia.